New hope for rare brain disease: platform trial targets PSP
NCT ID NCT07173803
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 6 times
Summary
This study tests several experimental treatments for progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. About 440 people with early-stage PSP will receive one of the treatments or a placebo. The goal is to see if any of the treatments can slow down the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY(PSP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- New study aims to spot Parkinson's early with simple blood, urine, and stool tests
- Scientists map Brain's 'Roads' to predict dementia spread
- AI reads faces and voices to spot Parkinson's
- Massive brain disease database aims to unlock secrets of Alzheimer's and ALS
- DNA hunt for rare brain disease genes begins